Valuation: Personalis, Inc.

Capitalization 737M 636M 582M 550M 1.01B 71.38B 1.04B 6.94B 2.7B 33.6B 2.77B 2.71B 117B P/E ratio 2026 *
-6.88x
P/E ratio 2027 * -7.86x
Enterprise value 576M 497M 455M 430M 793M 55.81B 813M 5.43B 2.11B 26.27B 2.16B 2.12B 91.75B EV / Sales 2026 *
7.32x
EV / Sales 2027 * 5.92x
Free-Float
72.99%
Yield 2026 *
-
Yield 2027 * -
1 day+8.31%
1 week+20.89%
Current month+39.95%
1 month+21.85%
3 months-6.70%
6 months-6.70%
Current year-2.95%
1 week 6.28
Extreme 6.28
7.75
1 month 4.96
Extreme 4.955
7.75
Current year 4.96
Extreme 4.955
11.5
1 year 3.84
Extreme 3.84
11.5
3 years 0.89
Extreme 0.8906
11.5
5 years 0.89
Extreme 0.8906
28.47
10 years 0.89
Extreme 0.8906
53.46
Manager TitleAgeSince
Chief Executive Officer 57 01/03/2023
Chief Executive Officer 65 30/12/2022
President 55 12/03/2026
Director TitleAgeSince
Director/Board Member 79 30/04/2019
Chairman 76 16/05/2022
Director/Board Member 72 05/03/2021
Change 5d. change 1-year change 3-years change Capi.($)
+8.38%+20.89%+55.75%+267.86% 737M
+1.06%+3.10%-13.35%-15.30% 43.14B
+3.32%-3.70%+28.70%+25.93% 33.02B
+2.70%+0.71%+273.12%+465.75% 31.32B
-3.02%-3.51%+14.75%-17.57% 28.9B
-0.38%-5.59%+23.25%+14.60% 25.34B
-0.22%-2.02% - - 14.78B
+1.61%-1.17%+128.23%+4,174.86% 13.35B
+1.31%+5.44%+8.96%+2.17% 12.5B
-2.28%-3.44%+33.45%+95.25% 11.99B
Average +1.21%+1.49%+61.43%+557.06% 21.51B
Weighted average by Cap. +0.67%-0.52%+60.94%+358.21%

Financials

2026 *2027 *
Net sales 78.74M 67.92M 62.22M 58.79M 108M 7.62B 111M 741M 289M 3.59B 295M 289M 12.53B 111M 95.75M 87.71M 82.88M 153M 10.75B 157M 1.05B 407M 5.06B 417M 408M 17.67B
Net income -107M -92.29M -84.54M -79.89M -147M -10.36B -151M -1.01B -392M -4.88B -402M -393M -17.03B -96.4M -83.14M -76.16M -71.97M -133M -9.33B -136M -908M -353M -4.39B -362M -354M -15.34B
Net Debt -161M -139M -127M -120M -221M -15.56B -227M -1.51B -589M -7.33B -603M -590M -25.58B -79.83M -68.85M -63.07M -59.6M -110M -7.73B -113M -752M -293M -3.64B -300M -293M -12.71B
Logo Personalis, Inc.
Personalis, Inc. is engaged in developing, marketing and selling advanced cancer genomic tests and analytics. The Company’s advanced genomic sequencing and analytics support the development of personalized cancer vaccines and other cancer immunotherapies. Its products include NeXT Personal, ImmunoI DNeXT, NeXT Personal Dx, NeXT Dx, whole exome sequencing (WES), and whole genome sequencing (WGS). NeXT Personal is a tumor-informed liquid biopsy test for the detection of minimal residual disease (MRD) and recurrence in cancer. NeXT Dx is a comprehensive tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient. The Company performed WGS on human samples for research projects, such as population sequencing initiatives. The Company’s tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and the development of personalized cancer therapies.
Employees
260
Date Price Change Volume
20/05/26 7.720 $ +9.66% 501,381
19/05/26 7.040 $ +4.76% 1,868,556
18/05/26 6.720 $ +5.66% 2,365,234
15/05/26 6.360 $ -5.22% 1,773,845
14/05/26 6.710 $ +5.01% 3,392,927
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
7.040USD
Average target price
10.86USD
Spread / Average Target
+54.22%

Quarterly revenue - Rate of surprise